|
1
|
Koh MY and Powis G: Passing the baton: The
HIF switch. Trends Biochem Sci. 37:364–372. 2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Walsh JC, Lebedev A, Aten E, Madsen K,
Marciano L and Kolb HC: The clinical importance of assessing tumor
hypoxia: Relationship of tumor hypoxia to prognosis and therapeutic
opportunities. Antiox Redox Signal. 21:1516–1554. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Carmeliet P: VEGF as a key mediator of
angiogenesis in cancer. Oncology. 69 (Suuppl 3):S4–S10.
2005.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hockel M and Vaupel P: Tumor hypoxia:
Definitions and current clinical, biologic, and molecular aspects.
J Natl Cancer Inst. 93:266–276. 2001.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Dhani N, Fyles A, Hedley D and Milosevic
M: The clinical significance of hypoxia in human cancers. Semin
Nucl Med. 45:110–121. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Vaupel P and Mayer A: Tumor hypoxia:
Causative mechanisms, microregional heterogeneities, and the role
of tissue-based hypoxia markers. Adv Exp Med Biol. 923:77–86.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Keith B and Simon MC: Hypoxia indicible
factors, stem cells and cancer. Cell. 129:465–472. 2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Evens AM, Schumacker PT, Helenowski IB,
Singh AT, Dokic D, Keswani A, Kordeluk E, Raji A, Winter JN,
Jovanovic BD, et al: Hypoxia inducible factor-alpha activation in
lymphoma and relationship to the thioredoxin family. Br J Haematol.
141:676–680. 2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Evens AM, Sehn LH, Farinha P, Nelson BP,
Raji A, Lu Y, Brakman A, Parimi V, Winter JN, Schumacker PT, et al:
Hypoxia-inducible factor-1α expression predicts superior survival
in patients with diffuse large B-cell lymphoma treated with R-CHOP.
J Clin Oncol. 28:1017–1024. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pazgal I, Boycov O, Shpilberg O, Okon E
and Bairey O: Expression of VEGF-C, VEGF-D and their receptor
VEGFR-3 in diffuse large B-cell lymphomas. Leuk Lymphoma.
48:2213–2220. 2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ruppert A, Dixon JG, Salles G, Wall A,
Cunningham D, Poeschel V, Haioun C, Tilly H, Ghesquieres H, Ziepert
M, et al: International prognostic indices in diffuse large B-cell
lymphoma: A comparison of IPI, R-IPI, and. NCCN-IPI. Blood.
135:2041–2048. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H and Thiele J: WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissues. International Agency for
Research on Cancer, Lyon, 2017.
|
|
13
|
Armitage JO: Staging non-Hodgkin lymphoma.
CA Cancer J Clin. 55:368–376. 2005.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Brown LF, Berse B, Jackman RW, Tognazzi K,
Guidi AJ, Dvorak HF, Senger DR, Connolly JL and Schnitt SJ:
Expression of vascular permeability factor (vascular endothelial
growth factor) and its receptors in breast cancer. Hum Pathol.
26:86–91. 1995.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Shahini L, Gasparov S, Petrusevska G,
Manxhuka Kerliu S, Veselaj F, Kurshumliu F and Kavaja F: Clinical
significance of VEGF-A and microvessel density in diffuse large
B-cell lymphoma and low-grade follicular lymphoma. Acta Clin Croat.
56:588–593. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gratzinger D, Zhao S, Tibshirani RJ, His
ED, Hans CP, Pohlman B, Bast M, Avigdor A, Schiby G, Nagler A, et
al: Prognostic significance of VEGF, VEGF receptors, and.
Microvessel density in diffuse large B cell lymphoma treated with
anthracycline-based chemotherapy. Lab Investig. 88:38–47.
2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yang J, Li W, He X, Zhang G, Yue L and
Chai Y: VEGF overexpression is a valuable prognostic factor for
non-Hodgkin's lymphoma: Evidence from a systematic meta-analysis.
Dis Markers. 2015(786790)2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Nagao A, Kobayashi M, Koyasu S, Chow CCT
and Harada H: HIF-1 dependent reprogramming of glucose metabolic
pathway of cancer cells and its therapeutic significance. Int J Mol
Sci. 20(238)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhong H, De Marzo AM, Laughner E, Lim M,
Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons
JW: Overexpression of hypoxia inducible factor 1 alpha in common
human cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
20
|
Wu X, Pertovaara H, Korkola P, Vornanen M,
Eskola H and Kellokumpu-Lehtinen PL: Glucose metabolism correlated
with cellular proliferation in diffuse large B-cell lymphoma. Leuk
Lymphoma. 53:400–405. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Maxwell PH, Dachs GU, Gleadle JM, Nicholls
LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW and Ratcliffe PJ:
Hypoxia-inducible factor 1 modulates gene expression in solid
tumors and influences both angiogenesis and tumor growth. Proc Natl
Acad Sci USA. 94:8104–8109. 1997.PubMed/NCBI View Article : Google Scholar
|
